Drug Type Antibody |
Synonyms- |
Target |
Action modulators |
Mechanism TL1A modulators(Tumor necrosis factor superfamily member 15 modulators), α4β7 modulators(Integrin alpha-4/beta-7 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Immune System Diseases | Preclinical | United States | 01 Jun 2026 | |
| Inflammation | Preclinical | United States | 01 Jun 2026 |






